688526 科前生物
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)1.85310.2389.83310.79912.316
总资产报酬率 ROA (%)1.6489.0198.3428.73810.092
投入资产回报率 ROIC (%)1.7659.7479.0199.52111.172

边际利润分析
销售毛利率 (%)64.00266.97363.75672.09373.611
营业利润率 (%)39.64350.86846.59143.14846.612
息税前利润/营业总收入 (%)34.89044.68539.97736.76840.267
净利润/营业总收入 (%)34.58343.90040.50137.17640.863

收益指标分析
经营活动净收益/利润总额(%)102.34988.33589.957112.82199.502
价值变动净收益/利润总额(%)5.0078.4478.5822.0411.735
营业外收支净额/利润总额(%)-0.108-0.327-0.163-0.339-0.023

偿债能力分析
流动比率 (X)7.4196.3985.3363.3844.105
速动比率 (X)7.0946.0835.0653.1933.834
资产负债率 (%)10.61611.48512.29617.84520.307
带息债务/全部投入资本 (%)2.8272.5712.7979.7289.042
股东权益/带息债务 (%)3,365.1833,707.9163,398.015910.127970.482
股东权益/负债合计 (%)842.026770.650712.912460.132392.198
利息保障倍数 (X)-7.407-7.425-6.115-5.897-6.356

营运能力分析
应收账款周转天数 (天)119.608117.489127.304110.821106.339
存货周转天数 (天)154.142154.864142.568190.461189.534